Related Experiment Videos
Influence of an impeller centrifugal pump on blood components in chronic animal experiments
Y Taenaka1, K Inoue, T Masuzawa
1Department of Artificial Organs, Research Institute, Osaka, Japan.
Insights
This study found that a novel centrifugal pump (CP) did not significantly alter key blood components in goats during chronic use. The device shows promise for long-term implantation without causing blood damage.
Area of Science:
- Biomedical Engineering
- Hematology
- Medical Devices
Background:
- Centrifugal pumps (CPs) are used in medical devices but can potentially damage blood components.
- Evaluating the hemocompatibility of new CP designs is crucial for long-term clinical applications.
Purpose of the Study:
- To assess the impact of a novel centrifugal pump (CP) on blood components in a chronic animal model.
- To determine the hemocompatibility of the CP for potential long-term use.
Main Methods:
- A chronic animal experiment was conducted on four goats (63-75 kg).
- A centrifugal pump (CP) replaced an existing pulsatile ventricular assist device after a 2-week recovery period.
- Antithrombotic therapy was administered using cilostazol (30 mg/kg/day).
- Blood parameters including hematocrit, plasma free hemoglobin, LDH, ADP, platelet count, fibrinogen, and antithrombin III were analyzed before and after CP use.
Main Results:
- No significant changes were observed in hematocrit, plasma free hemoglobin, lactic acid dehydrogenase, adenosine diphosphate, platelet count, fibrinogen, or antithrombin III.
- No morphological changes such as deformation or pseudopods were noted in platelets.
Conclusions:
- The evaluated centrifugal pump (CP) demonstrated excellent hemocompatibility in a chronic animal model.
- The CP did not induce significant damage to blood components, indicating its potential for safe, long-term application.
Abstract:
A chronic animal experiment was designed to examine the changes in blood components induced by the use of a centrifugal pump (CP). In the pump, an impeller spins in a blood chamber by magnetic coupling with a rotating magnet outside the blood chamber. A pulsatile ventricular assist device was implanted between the left atrium and the descending aorta in four goats weighing from 63 to 75 kg; the CP was installed to replace the assist device, without surgery and anesthesia, more than 2 weeks later when the influences of implantation surgery were diminished. Antithrombotic therapy was performed with oral administration of an antiplatelet agent, cilostazol, a cyclic adenosine monophosphate phosphodiesterase at a dose of 30 mg/kg/day. No significant differences were observed in any of the following parameters: 1) hematocrit, 2) plasma free hemoglobin, 3) lactic acid dehydrogenase, 4) adenosine diphosphate, 5) platelet count, 6) fibrinogen, and 7) antithrombin III, between the data before and after the use of the CP, nor were deformation or pseudopods of platelets seen. The CP developed in the authors' institute and evaluated in this study did not damage blood components, and it proved to be a promising device for long-term use.